ANMI SA is a precursor supplier for radiometal labeled radiopharmaceuticals and a global service provider in the nuclear medicine field, located in Liège, Belgium.
ANMI has developed innovative solutions to facilitate the synthesis of these theranostic radiopharmaceuticals and to ease their daily production in hospitals. These solutions are scalable and adaptable to a large range of peptide and non-peptide-based radiopharmaceutical precursors.
The company's expertise is based on a strong market and regulatory knowledge of the nuclear medicine area and can provide premium quality products and services.
ANMI's vision is focused on increasing patient access to new highly specific theranostic radiopharmaceuticals through straight forward and cost effective production processes.
More information to come,
October 2015 - ANMI and IC Medical signed an exclusive distribution agreement for the supply of ANMI’s products including PSMA-11 for diagnosis and management of prostate cancer in the Netherlands.Download the press release
September 2015 - ANMI (BELGIUM) and Eczacibaşi - Monrol signed an exclusive distribution agreement for the supply of ANMI’s products including PSMA-11 for diagnosis and management of prostate cancer in 48 countries.Download the press release